METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY

摘要

Methods for developing engineered T cells for immunotherapy that are both non alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T cells by inactivating both genes encoding target for an immunosuppressive agent and T cell receptor in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases in particular TALE nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides to precisely target a selection of key genes in T cells which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.